FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2564015282> ?p ?o ?g. }

• W2564015282 abstract "Abstract Introduction: AL amyloidosis (AL) is a clonal plasma cell disease with a median survival of 10–14 months without therapy. Phase II studies report remission rates in up to 50% of patients (pts) after high-dose melphalan (HDM) and autologous stem cell transplantation (ASCT). We retrospectively analysed AL pts who underwent HDM and ASCT at the Hammersmith Hospital in London since 1996. Patients and methods: 19 pts (12 m, 7 f), median age 51 y (40 – 63 y) with lambda (14) or kappa (5) AL (2 pts with multiple myeloma stage IA) had the following leading organ involvements: 10 kidney, 3 cardiac, 3 liver or gut, 3 other. 12 pts had more than 2 involved organs. According to risk criteria for HDM (Comenzo and Gertz, 2002) 12 pts were high, 2 pts intermediate and 5 pts low risk. Stem cells were mobilised with Cyclophosphamide (4 g/m2) in 3 pts, Etoposide (1.6 g/m2) in 1 patient, G-CSF alone in 14 pts, 1 bone marrow harvest was performed. Melphalan dose was: 8 pts 200 mg/m2, 5 pts 140 mg/m2, 6 pts 100 mg/m2. The median number of infused stem cells was 3.45 x 106 CD 34+ /kg bw (1.96 – 11.3 x 106 CD 34+ /kg bw). Results: Treatment related mortality (TRM) was 26%. In 14 patients who survived longer than 100 days from ASCT 6 pts achieved a haematological remission (5 a complete remission, 1 a partial remission) but in 8 patients no remission was achieved: 2 pts received a second ASCT, 2 pts further chemotherapy, 2 pts required haemodialysis. The mean survival from HDM and ASCT is 58.1 months (SD 9.64 months, 95% CI 39.21 – 76.99). The 1 - year and 2 - years overall survival from HDM and ASCT was 73% and 62%, respectively. The overall survival dropped to 42% after 6 years and the main cause of death was progressive or relapsed AL. Conclusions: HDM and ASCT is feasible for patients with AL, however, TRM was high at 26% in a group of maily high risk patients. 62% of patients survived longer than 2 years, but disease relapse and deaths from relapsed or progressive disease occurred after longer than 2 years from HDM. Thus, new treatment strategies have to be investigated to treat disease progress and relapse in order to improve the long-term survival after HDM and ASCT in patients with AL." @default.
• W2564015282 created "2017-01-06" @default.
• W2564015282 creator A5006511538 @default.
• W2564015282 creator A5012622762 @default.
• W2564015282 creator A5039305143 @default.
• W2564015282 creator A5074115908 @default.
• W2564015282 creator A5078806215 @default.
• W2564015282 date "2005-11-16" @default.
• W2564015282 modified "2023-10-14" @default.
• W2564015282 title "Long Term Survival Analysis after High-Dose Melphalan Chemotherapy Followed by Autologous Stem Cell Transplantation for Treatment of AL Amyloidosis: A Single Centre Experience." @default.
• W2564015282 doi "https://doi.org/10.1182/blood.v106.11.5503.5503" @default.
• W2564015282 hasPublicationYear "2005" @default.
• W2564015282 type Work @default.
• W2564015282 sameAs 2564015282 @default.
• W2564015282 citedByCount "0" @default.
• W2564015282 crossrefType "journal-article" @default.
• W2564015282 hasAuthorship W2564015282A5006511538 @default.
• W2564015282 hasAuthorship W2564015282A5012622762 @default.
• W2564015282 hasAuthorship W2564015282A5039305143 @default.
• W2564015282 hasAuthorship W2564015282A5074115908 @default.
• W2564015282 hasAuthorship W2564015282A5078806215 @default.
• W2564015282 hasConcept C126322002 @default.
• W2564015282 hasConcept C141071460 @default.
• W2564015282 hasConcept C159654299 @default.
• W2564015282 hasConcept C203014093 @default.
• W2564015282 hasConcept C2776364478 @default.
• W2564015282 hasConcept C2776694085 @default.
• W2564015282 hasConcept C2776755627 @default.
• W2564015282 hasConcept C2778119113 @default.
• W2564015282 hasConcept C2778684742 @default.
• W2564015282 hasConcept C2779050716 @default.
• W2564015282 hasConcept C2779551797 @default.
• W2564015282 hasConcept C2911091166 @default.
• W2564015282 hasConcept C36394416 @default.
• W2564015282 hasConcept C71924100 @default.
• W2564015282 hasConcept C90924648 @default.
• W2564015282 hasConceptScore W2564015282C126322002 @default.
• W2564015282 hasConceptScore W2564015282C141071460 @default.
• W2564015282 hasConceptScore W2564015282C159654299 @default.
• W2564015282 hasConceptScore W2564015282C203014093 @default.
• W2564015282 hasConceptScore W2564015282C2776364478 @default.
• W2564015282 hasConceptScore W2564015282C2776694085 @default.
• W2564015282 hasConceptScore W2564015282C2776755627 @default.
• W2564015282 hasConceptScore W2564015282C2778119113 @default.
• W2564015282 hasConceptScore W2564015282C2778684742 @default.
• W2564015282 hasConceptScore W2564015282C2779050716 @default.
• W2564015282 hasConceptScore W2564015282C2779551797 @default.
• W2564015282 hasConceptScore W2564015282C2911091166 @default.
• W2564015282 hasConceptScore W2564015282C36394416 @default.
• W2564015282 hasConceptScore W2564015282C71924100 @default.
• W2564015282 hasConceptScore W2564015282C90924648 @default.
• W2564015282 hasLocation W25640152821 @default.
• W2564015282 hasOpenAccess W2564015282 @default.
• W2564015282 hasPrimaryLocation W25640152821 @default.
• W2564015282 hasRelatedWork W159768456 @default.
• W2564015282 hasRelatedWork W2002099958 @default.
• W2564015282 hasRelatedWork W2014454786 @default.
• W2564015282 hasRelatedWork W2049733656 @default.
• W2564015282 hasRelatedWork W2081068834 @default.
• W2564015282 hasRelatedWork W2083725549 @default.
• W2564015282 hasRelatedWork W2435256000 @default.
• W2564015282 hasRelatedWork W2551633428 @default.
• W2564015282 hasRelatedWork W2992485704 @default.
• W2564015282 hasRelatedWork W4293043482 @default.
• W2564015282 isParatext "false" @default.
• W2564015282 isRetracted "false" @default.
• W2564015282 magId "2564015282" @default.
• W2564015282 workType "article" @default.